If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Subscribe To Our Newsletter & Stay Updated
